PGT-M Explained: Single-Gene Testing Before Embryo Transfer
Key Takeaways
PGT-M combines IVF, blastocyst biopsy, and a lab assay built around a known single-gene (monogenic) variant. It lowers the chance of transferring an embryo affected by that condition. It does not guarantee pregnancy, live birth, or a “risk-free” baby.
What PGT-M is
PGT-M — preimplantation genetic testing for monogenic disorders — was previously often called PGD. The lab looks for the specific familial mutation (or a validated linked strategy), not for every possible disease in the genome.
It improves embryo selection for that target condition. It does not replace counseling, prenatal care, or realistic IVF expectations.
Who it is used for
PGT-M is usually considered when:
- one or both partners carry a known pathogenic variant,
- there is a meaningful risk of transmitting a monogenic disorder,
- the familial mutation is identified (or can be confirmed),
- the couple is prepared for IVF, biopsy, freezing, and possibly a delayed transfer.
Typical contexts include cystic fibrosis, thalassemia, sickle cell disease, Huntington disease, and selected cancer-predisposition syndromes — always depending on the genetics report and national rules.
Carrier status alone is not enough. The laboratory needs a precise molecular target before embryo analysis is trustworthy.
How the PGT-M process works
| Step | What happens |
|---|---|
| 1 | Genetic counseling and assay design / validation |
| 2 | IVF stimulation and egg retrieval |
| 3 | Fertilisation (often ICSI) and culture to blastocyst |
| 4 | Embryo biopsy (usually trophectoderm) |
| 5 | Targeted genetic testing of the biopsy |
| 6 | Ranking embryos not found to carry the targeted condition |
| 7 | Transfer — often frozen, after results |
The first step is frequently underestimated. Without a validated test design, a “fast” PGT-M request is not safer — it is less reliable.
Why preparation takes time
Before the first biopsy:
- confirm the exact familial variant on official reports,
- design probes / linkage markers when needed,
- prepare controls and quality checks,
- align IVF timing with the genetics lab calendar.
Because biopsy, genetics, and freezing are often billed separately from a base IVF cycle, review how add-ons are itemised on the cost of IVF page.
What PGT-M can and cannot do
Can: reduce the chance of transferring an embryo affected by the targeted monogenic condition.
Cannot:
- guarantee implantation or live birth,
- screen every chromosomal problem unless PGT-A (or another test) is separately planned,
- create embryos if none develop,
- promise that an unaffected embryo will always be available.
Some cycles end with no transferable unaffected embryo. That outcome is hard — and should be named before stimulation starts.
Morphology grades (4AA, 4BB, and so on) still describe appearance only; they do not replace genetic results — see IVF embryo grading.
Why counseling matters
Good PGT-M care discusses:
- which condition is targeted and which is not,
- result categories (affected / unaffected / inconclusive),
- whether carrier embryos are acceptable for transfer in that scenario,
- whether confirmatory prenatal testing is still recommended,
- what happens if no embryo is suitable,
- legal limits in the country of treatment (including Turkey’s assisted-reproduction rules).
These decisions are medical, practical, and sometimes ethical at once.
Related reading
- Can PGT be used for sex selection?
- IVF embryo grading explained
- IVF risks and practical considerations
FAQ
Is PGT-M the same as standard IVF?
No. It uses IVF as the platform, then adds biopsy and targeted testing for a known inherited condition.
Does PGT-M guarantee a healthy baby?
No. It lowers the chance of transferring an embryo affected by the targeted disorder. It cannot guarantee pregnancy or eliminate every medical risk.
Can PGT-M be done without knowing the exact mutation?
Usually no. The laboratory needs a clearly identified familial variant or a validated strategy first.
Can a cycle end with no transferable embryo?
Yes — if no embryo develops adequately, if embryos are affected, or if unaffected embryos are not available.
Is prenatal testing still needed after PGT-M?
Often yes. Many programmes still recommend confirmatory prenatal testing because embryo testing, while highly useful, is not considered infallible.
Is PGT-M the same as PGT-A?
No. PGT-M targets a specific monogenic disease. PGT-A looks at chromosome copy number. They answer different questions and may be combined only when clinically justified.
Sources
- American Society for Reproductive Medicine. Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion (2023).
- ESHRE PGT-M Working Group. ESHRE PGT Consortium good practice recommendations for the detection of monogenic disorders.
- American College of Obstetricians and Gynecologists. Preimplantation Genetic Testing.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.